Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01657877 · ClinicalTrials.gov registry record · Phase 2

Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice

A Phase 2 study of Caries, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
100
Enrollment target
1
Study location

NCT01657877 is a Phase 2 study of Caries that has completed, run by GlaxoSmithKline. The registered enrollment target is 100 participants, above the 46-participant average among 7 other Caries trials with a reported enrollment target (117% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01657877, a Phase 2 study of Caries, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

In situ study to compare treatment effect on enamel remineralization potential, measured by surface microhardness recovery (SMHR) and Enamel Fluoride Uptake (EFU). The study will explore the efficacy of an experimental sodium monofluorophosphate (SMFP) dentifrice containing calcium sodium phosphosilicate (CSP) in comparison to an experimental SMFP only dentifrice.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Calcium sodium phosphosilicate
  • DRUG Sodium monoflurophosphate

Study Locations (1)

Indiana

  • Indiana University School of Dentistry - Indianapolis

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2012-05
Est. Completion 2013-06
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT01657877

The ClinicalTrials.gov registry entry for NCT01657877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 46-participant average among 7 other Caries trials with a reported enrollment target (117% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Caries appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01657877 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT01657877 about?

NCT01657877 is a clinical study titled "Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice". In situ study to compare treatment effect on enamel remineralization potential, measured by surface microhardness recovery (SMHR) and Enamel Fluoride Uptake (EFU). The study will explore the efficacy of an experimental sodium monofluorophosphate (SMFP) dentifrice containing calcium sodium phosphosil...

What is the current status of trial NCT01657877?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2012-05. Estimated completion is 2013-06.

What conditions does trial NCT01657877 study?

This clinical trial studies the following conditions: Caries.

What interventions are being tested in trial NCT01657877?

The interventions under investigation include: Placebo (DRUG), Calcium sodium phosphosilicate (DRUG), Sodium monoflurophosphate (DRUG).

Who is sponsoring clinical trial NCT01657877?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01657877 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Caries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.